Regeneron leaps into the blockbuster race to develop off-the-shelf immune cell cancer therapies
A year ago, Sanofi agreed to pay Regeneron $1.8 billion-plus to partner on its anti-PD1 checkpoint program. Today, biotech heavyweight Regeneron is jumping into CAR …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
